Differential sensitivity to etoposide (VP-16)-induced S phase delay in a panel of small-cell lung carcinoma cell lines with G1/S phase checkpoint dysfunction

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 2, 2001, Pages 133-140

  Soues S ^a   Wiltshire, M ^a   Smith, P J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cell cycle; DNA fragmentation; DNA topoisomerase II; TP53 tumour suppressor gene; VP 16 213

Indexed keywords

DNA FRAGMENT; ETOPOSIDE; NOCODAZOLE;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MITOSIS INHIBITION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SMALL CELL; DNA FRAGMENTATION; ETOPOSIDE; G1 PHASE; GENES, P53; HUMANS; LUNG NEOPLASMS; S PHASE; TUMOR CELLS, CULTURED;

EID: 0034919970     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000227     Document Type: Article

References (32)

1. Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma)
2. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
3. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II
4. Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213
5. Subpopulation induced cell-cycle delay in human tumor cells using 90° light scatter
6. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression
7. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial
8. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathology
9. Higher expression of topoisomerase II in lung cancers than normal lung tissues: Different expression pattern from topoisomerase I
10. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin
11. A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer
12. Predicting etoposide toxicity: Relationship to organ function and protein binding
13. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles
14. Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis and DNA strand size in cultures of human leukemic lymphoblasts
15. Differential inactivation of Cdkn2 and Rb protein in non-small-cell and small-cell lung-cancer cell-lines
16. A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14, 18)(q32, q21)
17. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
18. DNA topoisomerase poisons as anti-tumor drugs
19. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
20. Apoptotic death in epithelial cells: Cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation
21. Effect of the exposure dose of etoposide on the cell growth and cell kinetics of human ovarian cancer cells
22. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan
23. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study
24. Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukemia cells by facilitated G2 to M transition: Implications for gene therapy
25. p53 and the integrated cellular response to DNA damage
26. Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line
27. Multilevel therapeutic targeting by topoisomerase inhibitors
28. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small cell lung cancer cells
29. Cell cycle checkpoint evasion and protracted cell cycle arrest in X-irradiated small cell lung carcinoma cells
30. Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy
31. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity
32. A pragmatic approach to the analysis of DNA histograms with a definable G1 peak